English
Home > Products > CAS NO 70458-96-7

China CAS NO 70458-96-7 Factory

Our solutions are greatly recognized and reliable by customers and will fulfill continuously altering financial and social requirements for CAS NO 70458-96-7,70458-96-7,Norfloxacin API,Norfloxacin, Our enterprise warmly welcome close friends from everywhere in the environment to go to, examine and negotiate organization.
CAS NO 70458-96-7, Further, we're supported by highly experienced and knowledgeable professionals, who have immense expertise in their respective domain. These professionals work in close coordination with each other to provide our clients an effective range of products and solutions.

Related Products

Hot Products

  • 4-(hidroximetil)-5-metil-1,3-dioxol-2-one

    4-(hidroximetil)-5-metil-1,3-dioxol-2-one

    Product Name:4-(hidroximetil)-5-metil-1,3-dioxol-2-one
    Molecular Formula:C5H6O4
    Molecular Weight:130.1
    CAS Registry Number:91526-18-0
  • Gestonoronacetat

    Gestonoronacetat

    Product Name:Gestonoronacetat
    Molecular Formula:C22H30O4
    Molecular Weight:358.47
    CAS Registry Number;31981-44-9
  • 4-Bromopyridine hydrochloride

    4-Bromopyridine hydrochloride

    Product Name:4-Bromopyridine hydrochloride
    Molecular Formula:C5H5BrClN
    Molecular Weight:194.46
    CAS Registry Number:19524-06-2
  • 2-TRIFLUOROMETHYL-4-CHLOROPYRIDINE

    2-TRIFLUOROMETHYL-4-CHLOROPYRIDINE

    Product Name:2-TRIFLUOROMETHYL-4-CHLOROPYRIDINE
    Molecular Formula:C6H3ClF3N
    Molecular Weight:181.54
    CAS Registry Number:131748-14-6
  • 2'-Deoxyguanosine monohydrate

    2'-Deoxyguanosine monohydrate

    Product Name:2'-Deoxyguanosine monohydrate
    Molecular Formula:C10H15N5O5
    Molecular Weight:285.26
    CAS Registry Number:312693-72-4
  • 3,5-Dichlorosalicylic acid

    3,5-Dichlorosalicylic acid

    Product Name:3,5-Dichlorosalicylic acid
    Molecular Formula:C7H4Cl2O3
    Molecular Weight:207.01
    CAS Registry Number:320-72-9
  • Related Blog
  • Reviews

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept